$GRCE

$1.81 -$0.12 (6.22%) Close

$GRCE Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Company Executives

$GRCE Management Team

Dr. Roderick Carter

Independent Chairman of the Board

Age -

Compensation -

Sex Male

Mr. Prashant Kohli

Chief Executive Officer

Age 51

Compensation -

Sex Male

Mr. Robert Delaversano

Principal Financial Officer

Principal Accounting Officer

Age 52

Compensation -

Sex Male

Ms. Carrie D'Andrea

Vice President - Clinical Operations

Age 51

Compensation -

Sex Female

Mr. Amresh Kumar

Vice President - Program Management

Age 43

Compensation -

Sex Male

Dr. R. Loch Macdonald

Chief Medical Officer

Age -

Compensation -

Sex Male

Name / Title	Age	Compensation	Sex
Dr. Roderick Carter Independent Chairman of the Board	-	-	Male
Mr. Prashant Kohli Chief Executive Officer	51	-	Male
Mr. Robert Delaversano Principal Financial Officer Principal Accounting Officer	52	-	Male
Ms. Carrie D'Andrea Vice President - Clinical Operations	51	-	Female
Mr. Amresh Kumar Vice President - Program Management	43	-	Male
Dr. R. Loch Macdonald Chief Medical Officer	-	-	Male

Board of Directors

From the proxy statement filed Jul 28, 2026

Directors

serving now

Independent

4 of 4

stated in the proxy; 1 not stated

Average tenure

3.4 years

from year joined

CEO also chairs the board

Vimal Kavuru

Director	Age	On board	Independent	Committees	Other public boards	2026 pay
Vimal Kavuru Board chair	57	2021 5 years	Independent	Compensation Committee · Chair Nominating and Corporate Governance Committee · Chair	None stated	$124,467
A. Brian Davis	59	2023 3 years	Independent	None stated	None stated	$89,467
S. George Kottayil	63	2023 3 years	Independent	None stated	None stated	$65,467
Prashant Kohli CEO	54	2023 3 years	Not stated	None stated	None stated	Paid as CEO
Edward Neugeboren	57	2023 3 years	Independent	None stated	Matinas Biopharma, Inc.	$81,467

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

2 disclosed in the proxy filed Jul 28, 2026

Shore Pharma LLC

an entity held in a trust for the benefit of immediate family members of Vimal Kavuru, the Chair of the Company's Board of Directors

Amount not stated

2025

Purchase of common stock, 2025 Pre-Funded Warrants and 2025 Common Warrants in the 2025 Private Placement.

With the Company Open in proxy

ADAR1 Partners, LP, AIGH Investment Partners, LP, and SS Pharma LLC

each a beneficial owner of more than 5% of the common stock prior to the 2025 Private Placement

Approximately $5.7 million

2025

Purchase of common stock, 2025 Pre-Funded Warrants and 2025 Common Warrants in the 2025 Private Placement; the stated gross proceeds are an aggregate for all related parties in the placement.

With the Company Open in proxy

Comments

Company Executives

$GRCE Management Team

Dr. Roderick Carter

Mr. Prashant Kohli

Mr. Robert Delaversano

Ms. Carrie D'Andrea

Mr. Amresh Kumar

Dr. R. Loch Macdonald

Board of Directors

Related-party transactions